Navigation Links
Story ideas from the Journal of Lipid Research
Date:1/10/2008

Metabolic syndrome, a collection of related abnormalities like hypertension, obesity, insulin resistance, and excess cholesterol, poses a major risk for developing heart disease and diabetes. Individuals with a genetic predisposition to high cholesterol (familial hyperlipidemia or FH) can be especially vulnerable to metabolic syndrome, but researchers have now found that blocking the enzyme stearoyl-CoA desaturase-1 (SCD1), which helps synthesize unsaturated fatty acids, greatly improves the profile of FH-mice affected by metabolic syndrome.

Previous mouse studies on SCD1 found that blocking this enzyme could reduce obesity in normal mice; Michael Hayden and colleagues wondered whether such a protective effect would extend to mice with excess cholesterol levels.

They mimicked FH in mice by knocking out the LDL receptor, causing a cholesterol buildup. When fed a high-fat Western diet, these mice develop obesity and diabetes in adulthood. However, when the researchers also knocked out SCD1, the mice improved dramatically, accumulating far less fat in their liver, which in turn led to fewer triglycerides in the blood, increased insulin sensitivity, and less weight gain. These results highlight that SCD1 might be a potential drug target for FH individuals who have developed other components of metabolic syndrome


'/>"/>

Contact: Nick Zagorski
nzagorski@asbmb.org
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1

Related biology news :

1. The surprising story of Charles Darwin and his homeopathic doctor
2. Story tips from the Department of Energys Oak Ridge National Laboratory, December 2007
3. Story ideas from the Journal of Lipid Research
4. Journal Sleep: Insomniacs are more likely to report a family history of the sleep disorder
5. Nanotechnology and the media: The inside story
6. Rebuilding the evolutionary history of HIV-1 unravels a complex loop
7. Story ideas from the Journal of Biological Chemistry
8. Story tips from the Department of Energys Oak Ridge National Laboratory, October 2007
9. Story ideas from Molecular & Cellular Proteomics
10. Microfossils disclose geologic history of eastern California
11. New study sheds light on Galápagos hawk evolutionary history
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... developing and commercializing products to treat rare diseases where ... it will be hosting an Investor Webcast Event Friday, ... origins of innate defense regulators (IDRs) as a new ... mucositis and the recently announced and published Phase 2 ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... ), a leading commercial provider of clinically actionable ... cancer patients, announces that clinical data featuring its ... concordance to tissue biopsy for the detection of ... The results from research sponsored by Sara Cannon ...
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... 7, 2016  Vyriad Inc. announced today the appointment ... Board of Directors. "We are delighted to ... business and develop our oncolytic viruses as the next ... Stephen Russell , MD, PhD, CEO of Vyriad. "Al ... vision and passion for making a difference for cancer ...
Breaking Biology Technology: